FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support potential PSVT treatment launch.

Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat ...

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex ...

Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat ...

Review question We reviewed the evidence for the benefits and harms of nasal saline irrigation in patients with chronic rhinosinusitis. Background Chronic rhinosinusitis is a common condition that is ...